Natural compounds as multitarget agents in Alzheimer’s diseases: evidence from in vivo and in vitro models
Overall, the available evidence suggests that natural compounds confer multitarget neuroprotective effects that directly engage with key pathological mechanisms underlying AD. Nonetheless, significant translational challenges remain, particularly with respect to bioavailability, compound standardisation, and clinical efficacy. Further robust, well-controlled clinical trials are essential to establish the therapeutic value of these agents as potential disease-modifying interventions for AD.
Authors
- Vicko Suswidiantoro (ORCID: https://orcid.org/0000-0002-6315-706X)
- Fadlina Chany Saputri (ORCID: https://orcid.org/0000-0002-6668-8915)
- Mitsuyasu Kato (ORCID: https://orcid.org/0000-0001-9905-2473)
- Khalid Rahman
- Choo Chee Yan
- Richard Johari James
- Donna Maretta Ariestanti
- Kim San Tang
Institutions
- Monash University Malaysia (MY)
- University of Tsukuba (JP)
- University of Indonesia (ID)
- Integrative Medicine Institute (US)
- Universiti Teknologi MARA System (MY)
- Liverpool John Moores University (GB)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.3389/fphar.2026.1766470
- Primary Topic
- Seaweed-derived Bioactive Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministrstvo za visoko šolstvo, znanost in tehnologijo
- Lembaga Pengelola Dana Pendidikan